The two-period crossover trial has the evident advantage that, by use o f w ithin-patient comparisons, the usual large between-patient variability is not used as a m easure to com pare treatments. A prerequisite, however, is that the order of the treatm ents does not sub stantially influence the outcome of the treatm ent, Crossover studies with a binary re sponse fsuch as yes/no or present/absent), although widely used for initial screening of new compounds, have not previously been studied for such order effects. This study uses a m athem atical model based on standard statistical tests to study to what extent such order effects, here identical to carryover effects, may reduce the power of delecting a treat m ent effect. It is concluded that, despite large carryover effects, the crossover study with a binary response rem ains a powerful method and that testing for carryover effects m akes sense only if the null hypothesis of no treatm ent effect cannot be rejected.
T he crossover design is widely used in clinical re search, especially in instances where a limited number of patients is available for a study, The main advantage of within-patient comparisons in compar ison to between-patient comparisons is that between-subject variability is not used in the compari sons. A prerequisite, however, for this type of trial is that the order of the treatments does not influence the outcome of the treatment. If the effect of the treatment administered in the first period carries over into the second period, then it may influence the measured response in the second period. This es sentially means that only symptomatic treatments qualify for crossover comparisons and curative treat ments do not.
Symptomatic treatments frequently have small curative effects, however, such as wound healing by vasodilators or, more recently, cardiac remodeling by afterload reduction. The treatment group that is treated with the effective compound first and with the less effective compound or placebo second is fre quently biased by carryover effect from the first pe riod to the second, whereas the alternative group that is treated in the reverse order is not so.1 For ex ample, of 73 reports of crossover trials published in 1989-1990,2 only 6 reported the data of the separate periods, In 5 of them (83%) this very type of carryover effect was demonstrable. Such a mechanism may cause a severe underestimation of the treatment re sults,2 and this possibility should, therefore, be as sessed in the analysis, Most of the reports on the subject of order effects so far have addressed crossover studies with a quan titative rather than binary response/1 1 (1 Although Hills and Armitage11 mentioned the tests of Gart12 and Prescott™ for crossover trials with a binary re sponse in their overview of methods in crossover clinical trials and Fidlcr1* 1 presented a model, little attention has been paid to those kinds of trials. A bi nary response is different from a quantitative re sponse in that it generally does not answer what ex actly can be expected in an individual. Rather it ad dresses whether or not a particular result has a predictive value, which of two treatments is better, or whether there is a treatment effect in the data. One might contend, therefore, that some undervalu ation of a difference in binary data is not that impor tant as long as it does not cause a type II error by in- dicating no difference were there is one. The main purpose of our analysis was to examine whether in crossover trials with a binary response a significant carryover effect does leave enough power in the data to demonstrate a treatm ent effect.
ASSESSMENT OF CARRYOVER AND TREA TM EN T EFFECT
In a crossover trial with two treatments and two treatment periods, patients are assigned in a random ized fashion to two symmetric groups that are given treatments A and B in a different order (Table I) . If groups are symmetric and the results are not influ enced by the order of the treatments, the probabili ties of treatment success in groups I and 2 should be virtually the same in each period for each treatment; pA being the probability of treatm ent success from treatment A and pu the probability of treatment suc cess from treatment B (Table I) , Results from the group that is treated with the less effective treatment or placebo after the more effective are in danger of being biased by carryover effect from the first period to the second.
Suppose treatment A is far less effective than treat ment B (Table I) . Then, if in group 2 treatment B has a carryover effect on the outcome of treatment A, the probability of treatment success changes from pB to pc. To detect a carryover effect we compare the out comes of treatm ent A in group 1 to the outcomes of treatment A in group 2; pA versus pc> an unpaired comparison. The am ount of carryover effect in group 2 is considered to be the difference between pc and pA. Carryover effect in group 1 (ineffective treatment period before effective treatment) is assumed to be negligible. Time effect is assumed to be negligible as well, because we study stable disease only.
It thus seems that neither a test for carryover effect in group 1 nor a test for tim e effects needs to be in cluded in our assessment. T reatm ent effect is as sessed by taking the two groups together, after w hich all outcomes of treatm ent A are com pared with those of treatm ent B in a paired comparison. The assum p tion that carryover effect in group 1 is negligible impli es that the test for carryover effect uses only half of the available data and m ight therefore be expected to be less sensitive. Sensitivity not only depends on sample size, however, but also on the size of differ ences and their variances.
S T A T IST IC A L M O DEL F O R T E S T IN G T R E A T M E N T A N D C A R R Y O V E R EFFECTS
We assume a unidirectional assessment w here p is betw een 0.0 (no m ore symptoms) and 1.0 (100% of patients rem ain sym ptom atic despite treatment). W hen carryover effect is in the data, pA for group 2 becomes pc ( Table I) . The difference betw een pc and pA is considered to be the am ount of carryover effect in the data. Fisher's exact test is used to determ ine w hether pc is significantly different from pA. Using the program of Bavry,15 the values for pc that should yield a significant carryover effect in 80% of the trials (i.e., power = 80%) are determ ined. A num ber of pa tients betw een 10 and 25 is chosen for both groups, because m any crossover trials have 20 to 50 patients. The values for pc are then used to determ ine w hether enough pow er is left in the data to dem on strate a significant treatm en t effect in crossover trials w ith significant carryover effect and a binary re sponse. 
CLINICAL TRIALS 199
CLEOPHAS AND v a n LIER To test the treatment effect, all data for treatment A are taken together and compared with data for treatment B. The power of this test depends not only on the probabilities pA and pB, but also on the corre lation between the treatment responses. This corre lation is expressed as p = pA/B ~~ P a , where pA/B is the probability of treatment success with treatment A, given that treatment B was successful. When p = 0, treatments A and B act independently. When pn equals pc> this would mean that the carryover effect in group 2 is not only significant but also maximal, given the amount of treatment effect. Considering this situation of maximal carryover effect, we calcu late the power of detecting treatment effects. The power of the McNemar test, with pB being equal to pc and various values for p , was calculated according to Bavry.15
RESULTS

Calculation of pc Values Yielding a Significant Result for Carryover Effect
For various numbers of patients and various values of pA (the probability of success with treatment A in period 1; Table I), the pc values (the probability of success with treatment A in period 2) are calculated so that a power of 80% will yield a significant test for carryover effect (pA versus Pc; a = 0.05). Table II shows that carryover effects (difference between pA and pc) as large as 0.60, 0.50, 0.40, and 0.35 are re quired for a significant test. For a -0.01, these values are approximately 0.70, 0,60, 0.50, and 0.45. Using these pc values, we then calculated the probability of detecting a treatment effect (i.e., power of testing treatment effect). We report minimal values of power only, i.e., the situation where pB = pc. Whenever pB < pc, we would have an even better power for testing treatment effect.
Power of Paired Comparison for Treatment Effect
When the result of treatment B (pB ) is taken equal to the maximal values of pc and treatments A and B act independently [p = 0), the probability or power of de tecting a treatment effect in the crossover situation when n is between 20 and 50 is always more than 94% (Table II) . Usually, however, treatments A and B do not act independently. With a negative correla tion between the two treatment modalities power is lost, and with a positive correlation it is augmented. Table III shows power values adjusted for different levels of p. With negative levels of p and 20 patients, the power for detecting a treatment difference is not less than 74%, which is approximately as large as that chosen for the test on carryover effect (80%). When more patients are admitted to the trial this value will be ~90%.
EXAMPLES
Suppose we have a negative crossover in which the probability of treatment success in group 2 pc (Table  IV) Therefore, in crossovers with a binary response and a negative result, it does make sense to test for carryover effect by comparing the two periods with the less effective treatment modalities. If a significant test is demonstrated, we obviously will find a sig nificant difference at a similar or even lower level of significance when taking the first period for estimat ing the difference between treatment A and B. Thus, it would seem appropriate for our purpose to disre gard the data of the second period in this particular situation (although the second period might still pro vide interesting information).
DISCUSSION
The power of crossover studies is frequently reduced by carryover effect. This is particularly so when a group that is treated with an effective treatment first is then treated with an ineffective treatment or pla cebo second. In studies with a quantitative response, this very effect may cause severe underestimation of the treatment effect.1 Studies with a binary response are different from studies with a quantitative re sponse, however, in that they are mostly designed to determine whether a treatment has any effect rather than the magnitude of that effect, One might contend, therefore, that underestimation in such studies is not important as long as the null hypothesis of no treatment effect doesn't have to be erroneously accepted. We demonstrate that in crossover trials with a binary response and significant carryover effect, the power of testing the treatment effect re mains substantial. This would imply that routinely testing for carryover effects in such studies is not necessary as long as the result of the treatment com parison is positive. When a study is negative it does make sense, however, to test for carryover effect by comparing pA and pc (Table I) .
When pA is significantly different from pc, we as sume that there is a carryover effect in group 2. In this situation, a parallel-group analysis of period 1 (pA versus pB ) can effectively be used to demonstrate a treatment effect. This will provide a significant difference at a similar or even lower level of signifi cance than the test for carryover effect. This occurs because pB equals pc w hen carryover effect is maxi mal. The difference between pB and pA will therefore be at least as large as the difference between pc and pA, and may be larger. Therefore, no further test for treatment effect seems to be required for our purposes, and it seems appropriate that the results of the second period be disregarded.
Considering that the influence of carryover effects in crossover trials with a binary response may not be a problem, we should shift our standards for choos ing this particular trial design and make use of its additional advantages more frequently. For exam ple, this design is particularly powerful for study of rapid relief of symptoms in chronic disease in which the long-term condition of the patient remains fairly stable.16 This is because between-subject variability is not a factor in a within-subject comparison. Also, we can make use of positive correlations between the treatment modalities tested, because the statistical power of testing treatment comparisons with a posi tive correlation can be largely enhanced by withinsubject comparisons.37 Further, none of the patients in the trial has to be treated throughout the trial with a less adequate dose or placebo, which is why a cross over design usually raises fewer ethical considera tions than does a parallel-group design in which one group is treated with placebo or less adequate dosage throughout the trial. Also, there is the advantage that patients can express their own opinions about which treatment they prefer. This is particularly important with subjective variables such as pain scores. The crossover design also does not require a large study group, because within-subject comparison facilitates the recruitment procedure and reduces costs. Fi nally, a double-blind design cannot be effectively ex ecuted in self-controlled studies without some kind of crossover element.
We therefore conclude that crossover studies with a binary response and positive results do not have to be tested for carryover effects. If such studies have a
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